台湾结直肠癌辅助治疗中口服 UFT/亚叶酸与 5-氟尿嘧啶/亚叶酸的成本最小化比较。
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
机构信息
Department of Surgery, Division of Colon & Rectal Surgery, Taipei Mackay Memorial Hospital, Taipei, Taiwan; Department of Surgery, Taipei Medical University; Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
School of Pharmacy, National Taiwan University, Taipei, Taiwan.
出版信息
J Comp Eff Res. 2019 Jan;8(2):73-79. doi: 10.2217/cer-2018-0078. Epub 2018 Dec 18.
AIM
Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer. This study aims to determine the most cost-effective treatment alternative between UFT/LV and 5-FU/LV in Stages II and III colorectal cancer from Taiwan's National Health Insurance perspective.
PATIENTS & METHODS: The costs were referenced directly from the National Health Insurance reimbursement price. Chemotherapy regimen considered for the cost analysis calculation was adapted from NSABP-C-06 study, and, a time saving calculation was also included. In addition, we compare the treatment outcome.
RESULT
A total cost saving of US$3620.80-$3709.16 per patient per treatment was achieved with the UFT/LV treatment. UFT/LV provides the comparable outcome to 5-FU/LV.
CONCLUSION
UFT/LV was the more cost-effective treatment as adjuvant chemotherapy.
目的
口服尿嘧啶替加氟/亚叶酸（UFT/LV）和静脉注射氟尿嘧啶（FU）/亚叶酸（LV）是 II 期和 III 期结直肠癌的常用辅助治疗方法。本研究旨在从台湾全民健康保险的角度确定 II 期和 III 期结直肠癌中 UFT/LV 和 5-FU/LV 之间最具成本效益的治疗选择。
患者和方法
成本直接参考全民健康保险报销价格。成本分析计算中考虑的化疗方案改编自 NSABP-C-06 研究，并包括节省时间的计算。此外，我们还比较了治疗结果。
结果
UFT/LV 治疗每例患者每例治疗可节省 3620.80-3709.16 美元的总成本。UFT/LV 提供与 5-FU/LV 相当的结果。
结论
UFT/LV 是更具成本效益的辅助化疗治疗方法。
Zotero 插件